{"organizations": [], "uuid": "1f1d41b78c23c3d4233f95c30252f2bd92a81728", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-seattle-genetics-and-astellas-rece/brief-seattle-genetics-and-astellas-receive-fda-breakthrough-therapy-designation-for-enfortumab-vedotin-idUSASC09TL3", "country": "US", "domain_rank": 408, "title": "BRIEF-Seattle Genetics And Astellas Receive FDA Breakthrough Therapy Designation For Enfortumab Vedotin", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-26T15:14:00.000+03:00", "replies_count": 0, "uuid": "1f1d41b78c23c3d4233f95c30252f2bd92a81728"}, "author": "", "url": "https://www.reuters.com/article/brief-seattle-genetics-and-astellas-rece/brief-seattle-genetics-and-astellas-receive-fda-breakthrough-therapy-designation-for-enfortumab-vedotin-idUSASC09TL3", "ord_in_thread": 0, "title": "BRIEF-Seattle Genetics And Astellas Receive FDA Breakthrough Therapy Designation For Enfortumab Vedotin", "locations": [], "entities": {"persons": [], "locations": [{"name": "seattle", "sentiment": "none"}], "organizations": [{"name": "brief-seattle genetics and astellas receive fda", "sentiment": "negative"}, {"name": "fda", "sentiment": "negative"}, {"name": "enfortumab vedotin reuters staff", "sentiment": "none"}, {"name": "seattle genetics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "seattle genetics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 26, 2018 / 12:16 PM / Updated 5 minutes ago BRIEF-Seattle Genetics And Astellas Receive FDA Breakthrough Therapy Designation For Enfortumab Vedotin Reuters Staff 1 Min Read March 26 (Reuters) - Seattle Genetics Inc: * SEATTLE GENETICS AND ASTELLAS RECEIVE FDA BREAKTHROUGH THERAPY DESIGNATION FOR ENFORTUMAB VEDOTIN IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER * SEATTLE GENETICS INC - COS ARE ALSO EVALUATING ENFORTUMAB VEDOTIN IN OTHER SOLID TUMORS, INCLUDING OVARIAN AND NON-SMALL CELL LUNG CARCINOMA Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-26T15:14:00.000+03:00", "crawled": "2018-03-26T15:26:29.043+03:00", "highlightTitle": ""}